Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided.

Abstract: The present invention relates preferably to ways of biologically treating liquids, and devices applicable in this respect. Processes and devices according to the present invention preferably relates to a system for biological treatment of liquid such as water, the system typically comprising a container having first and second gas supplies for creating a first and second circulating flow of liquid and bio-film carriers and preferably also for aerating the liquid. Preferred embodiments of a container according to the invention comprises an outflow channel extending along, and preferably throughout, a perimeter of an upper part of the container, the flow channel having a fluid penetrable wall section facing inwardly so that fluid may flow from the interior of the container, through the fluid penetrable wall section and into the outflow channel, and an outlet for leading fluid out from the outflow channel.

Abstract: The present invention relates preferably to ways of biologically treating liquids, and devices applicable in this respect. Processes and devices according to the present invention preferably relates to a system for biological treatment of liquid such as water, the system typically comprising a container having first and second gas supplies for creating a first and second circulating flow of liquid and bio-film carriers and preferably also for aerating the liquid. Preferred embodiments of a container according to the invention comprises an outflow channel extending along, and preferably throughout, a perimeter of an upper part of the container, the flow channel having a fluid penetrable wall section facing inwardly so that fluid may flow from the interior of the container, through the fluid penetrable wall section and into the outflow channel, and an outlet for leading fluid out from the outflow channel.

Abstract: The present invention relates to biological treatment and devices applicable in this respect. The closed container comprises a first inlet (20) and a first outlet (18), at least one vertically orientated tube (6) arranged in the container (2), the lower end of said tube being raised above the bottom of the container (2), a first gas supply (8) arranged at the lower end of said tube (6) for creating a first circulating flow (F1) of liquid and microfilm carriers through the vertically orientated tube, a second gas supply (16) arranged at the bottom and in the vicinity of the wall of the container for creating a second circulating flow (F2) of liquid and microfilm carriers. The invention additionally relates to a plurality of serially connected containers.

Abstract: New conjugates comprising fragments of amyloid proteins, which may be used in vaccines for the treatment, prevention and/or amelioration of diseases associated with deposition of amyloid proteins, such as, e.g. Alzheimers disease. Methods for treating, preventing and/or ameliorating amyloid-related diseases, by administering a conjugate comprising fragments of an amyloid protein to a subject in need thereof, thereby enabling the production of antibodies in the subject. Antibodies—being capable of interacting with pathological regions within an amyloid protein, and thereby preventing e.g. the formation of amyloid fibrils, plaques and/or deposits, and methods for passive immunization wherein an antibody as described above is administered to a subject in need thereof. Furthermore is provided specific fragments of the C-terminal part of amyloid beta (1-42), that when administered to a mammal generates antibodies, which specifically targets the soluble form of the highly amyloidogenic amyloid beta (1-42).